AKBA
AKBA
Positions held
Your positionsAKBA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
2026-10-01 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-22 · SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
2026-09-15 · SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
2026-09-14 · Akebia Therapeutics Doses First Patient in Phase 2 Ebribafusp Trial
2026-09-01 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 · Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
2026-08-06 · Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...
2026-08-05 · Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
2026-08-05 · Akebia Therapeutics Q2 Earnings Call Highlights
Price (daily)
Full chart · RSI · MACD · patterns